Ascorbic acid ( DrugBank: Ascorbic acid )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
10	シャルコー・マリー・トゥース病	7
97	潰瘍性大腸炎	2
206	脆弱Ｘ症候群	2
298	遺伝性膵炎	1

10. シャルコー・マリー・トゥース病

臨床試験数 : 41 / 薬物数 : 46 - (DrugBank : 9) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 15

diseases per page:

Showing 1 to 7 of 7 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs031190109	25/10/2019	03/10/2019	Ascorbic acid treatment for childhood Charcot-Marie-Tooth disease 1A	Ascorbic acid treatment for childhood Charcot-Marie-Tooth disease 1A - Ascorbic acid for CMT1A	Charcot-Marie-Tooth disease type 1A CMT1A;G600	ascorbic acid dayly intake	SHIOHAMA TADASHI	NULL	Recruiting	Not applicable	< 18age old	Both	12	Phase 2	Japan
2	JPRN-UMIN000036332	2019/06/15	28/03/2019	Ascorbic acid treatment for Charcot-Marie-Tooth disease type 1A	Ascorbic acid treatment for Charcot-Marie-Tooth disease type 1A - Ascorbic acid treatment for CMT1A	Charcot-Marie-Tooth diease type 1A	Ascorbic acid treatment: 20mg/kg/day, dayly	Chiba University	NULL	Pending	1years-old	Not applicable	Male and Female	10	Phase 1	Japan
3	NCT00484510 (ClinicalTrials.gov)	April 2007	8/6/2007	High Dose Ascorbic Acid Treatment of CMT1A	A Randomized, Placebo-controlled, Double Masked 120 Subject Futility Design Clinical Trial of Ascorb ...	Charcot-Marie-Tooth Disease, Type Ia	Drug: Ascorbic acid (Vitamin C);Drug: placebo	Wayne State University	Muscular Dystrophy Association;Charcot-Marie-Tooth Association	Completed	13 Years	70 Years	Both	110	Phase 2/Phase 3	United States
4	NCT00271635 (ClinicalTrials.gov)	January 2006	3/1/2006	Ascorbic Acid Treatment in CMT1A Trial (AATIC)	Phase 2 Study of Ascorbic Acid Treatment in Charcot-Marie-Tooth Type 1A	Charcot-Marie-Tooth Disease;Hereditary Motor and Sensory Neuropathies	Drug: Placebo;Drug: ascorbic acid	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	NULL	Completed	12 Years	25 Years	Both	13	Phase 2	Netherlands
5	EUCTR2006-000032-27-IT (EUCTR)	19/10/2005	14/03/2006	MULTICENTRE RANDOMISED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF LONG-TERM ASCORBIC ACIDTREATMENT IN ...	MULTICENTRE RANDOMISED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF LONG-TERM ASCORBIC ACIDTREATMENT IN ...	Charcot-Marie-Tooth disease type 1A CMT1A MedDRA version: 6.1;Level: HLGT;Classification code 100346 ...	Trade Name: CEBION 500MG 20CPR MAST.ARAN INN or Proposed INN: ACIDO ASCORBICO DC.IT INN or Proposed IN ...	ISTITUTO NEUROLOGICO CARLO BESTA	NULL	Not Recruiting			Female: yes Male: yes	202		Italy
6	JPRN-UMIN000001535	2005/04/01	01/01/2009	A multicenter, randomized open trial of ascorbic acidtreatment in Charcot-Marie-Tooth disease type 1 ...	A multicenter, randomized open trial of ascorbic acidtreatment in Charcot-Marie-Tooth disease type 1 ...	Charcot-Marie-Tooth disease 1A	Ascorbic acid (AA) treatment group (12 weeks oral AA (20mg/kg/day) no AA treatment group	New treatment strategies for intractable neuropathies based on its pathomechanism.The Research Grant ...	NULL	Complete: follow-up complete	15years-old	75years-old	Male and Female	60	Phase 1,2	Japan
7	EUCTR2004-004501-24-IT (EUCTR)	22/12/2004	13/02/2007	Multicentre, randomised, double blind, placebo controlled trial of ascorbic acidtreatment in Charcot ...	Multicentre, randomised, double blind, placebo controlled trial of ascorbic acidtreatment in Charcot ...	Charcot-Marie-Tooth Disease Type 1A CMT1A . MedDRA version: 6.1;Level: HLT;Classification code 10022 ...	Trade Name: CEBION 500*20CPR MAST 500MG Product Name: ACIDO ASCORBICO INN or Proposed INN: Ascorbic ac ...	ISTITUTO NEUROLOGICO CARLO BESTA	NULL	Not Recruiting			Female: yes Male: yes	200		Italy

First Previous1Next Last

先頭へ

97. 潰瘍性大腸炎

臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03581149 (ClinicalTrials.gov)	March 26, 2018	27/3/2018	Tolerability and Efficacy of Sodium Picosulfate/Magnesium Citrate Versus PEG/Ascorbic Acidin Ulcerat ...	Tolerability and Efficacy of Low-Volume Sodium Picosulfate/Magnesium Citrate Versus 2L Polyethylene ...	Ulcerative Colitis	Drug: Sodium Picosulfate/Magnesium Citrate Laxative;Drug: 2L polyethylene glycol/ascorbic acid	American University of Beirut Medical Center	NULL	Recruiting	18 Years	65 Years	All	68	Phase 4	Lebanon
2	NCT01929668 (ClinicalTrials.gov)	August 2013	23/8/2013	Comparison of 4L Polyethylene Glycol and 2L Polyethylene Glycol With Ascorbic Acidin Inactive UC Pat ...	Comparison of 4L Polyethylene Glycol and 2L Polyethylene Glycol With Ascorbic Acidin Patients With I ...	Ulcerative Colitis	Drug: polyethylene glycol;Drug: Ascorbic Acid	Kyungpook National University	NULL	Completed	18 Years	80 Years	Both	114	N/A	Korea, Republic of

First Previous1Next Last

206. 脆弱Ｘ症候群

臨床試験数 : 108 / 薬物数 : 91 - (DrugBank : 36) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 77

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-005460-42-ES (EUCTR)	07/07/2016	20/04/2016	Clinical trial to evaluate ascorbic acid(vitamin C) and tocopherol (vitamin E) in combination versus ...	Phase III clinical trial, double-blind, cross-way, to evaluate the safety and efficacy ascorbic acid ...	Fragile x syndrome MedDRA version: 19.0;Level: PT;Classification code 10017324;Term: Fragile X syndr ...	Product Name: Vitamin C INN or Proposed INN: Vitamin C Other descriptive name: ACIDUM ASCORBICUM D6 Pro ...	Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud	NULL	Not Recruiting			Female: no Male: yes		Phase 3	Spain
2	NCT01329770 (ClinicalTrials.gov)	December 2010	29/3/2011	Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X Syndrome	Phase II Double-blind Randomized Placebo-controlled 1-way Crossover Trial to Investigate Safety and ...	Fragile X Syndrome	Dietary Supplement: Ascorbic Acid(Vitamin C) and Alpha-tocopherol (Vitamin E);Dietary Supplement: Pl ...	Yolanda de Diego Otero	NULL	Completed	6 Years	18 Years	Male	30	Phase 2	Spain

First Previous1Next Last

298. 遺伝性膵炎

臨床試験数 : 95 / 薬物数 : 148 - (DrugBank : 51) / 標的遺伝子数 : 53 - 標的パスウェイ数 : 142

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2006-000087-83-GB (EUCTR)	19/12/2008	04/12/2007	EUROPAC2 trial to investigate the efficacy of ANTOX(vers) 1.2 and MGCT (magnesiocard) for the treatm ...	EUROPAC2 trial to investigate the efficacy of ANTOX(vers) 1.2 and MGCT (magnesiocard) for the treatm ...	Hereditary Pancreatitis and Idiopathic Chronic Pancreatitis MedDRA version: 13.1;Level: HLT;Classifi ...	Trade Name: Magnesiocard 2.5mmol Other descriptive name: MAGNESIUM ASPARTATE HYDROCHLORIDE Product Nam ...	University of Liverpool	The Royal Liverpool and Broadgreen University Hospitals NHS Trust	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	United Kingdom

First Previous1Next Last

先頭へ